Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

Feasibility of the Multiple Sclerosis Performance Test for Assessment of Functional Performance Measures in Patients With Multiple Sclerosis

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03926637

Enrollment

3073

Registered

2019-04-24

Start date

2019-06-17

Completion date

2022-12-05

Last updated

2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Clinically Isolated Syndrome

Brief summary

The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).

Interventions

OTHERMultiple Sclerosis Performance Test (MSPT)

Administered as specified in the treatment arm.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with applicable participant privacy regulations * Diagnosis of MS, including Clinically Isolated Syndrome * Ability to understand the audio and visual instructions for the test modules * Visual function, based on the investigator's clinical judgement that does not preclude an ability to interact with the Multiple Sclerosis Performance Test (MSPT). Key

Exclusion criteria

* Unable or unwilling to provide informed consent * Participants younger than 18 years of age, unless their parent or legal guardian provides the required signed and dated informed consent and authorization to use confidential health information and the participant provides assent in accordance with national and local subject privacy regulations NOTE: Other protocol defined Inclusion/

Design outcomes

Primary

Measure	Time frame
Percentage of Participants Completing All Modules	Baseline to Month 24
Percentage of Participants Completing Each Individual Module	Baseline to Month 24
Percentage of Participants Skipping Modules	Baseline to Month 24
Average Time to Complete the Multiple Sclerosis Performance Test (MSPT)	Baseline to Month 24
Average Time to Complete Individual MSPT Modules	Baseline to Month 24
Frequency of Reasons for Not Completing MSPT Modules	Baseline to Month 24
Frequency Distribution of Demographic Characteristics of Participants Failing to Complete Specific MSPT Modules	Baseline to Month 24

Countries

Czechia, France, Italy, Switzerland, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026